CareLit Fachartikel

Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG HD15 trial

C Kobe, A Engert, J Markova, H Haverkamp, HT Eich, RP Müller, A Holstein, D Kahraman, M Dietlein, P Borchmann, V Diehl · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 2012 · Heft 04

Dokument
1171325
CareLit-ID
Jahr
2012
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Autor:innen
C Kobe, A Engert, J Markova, H Haverkamp, HT Eich, RP Müller, A Holstein, D Kahraman, M Dietlein, P Borchmann, V Diehl
Ausgabe
Heft 04 / 2012
Seiten
–
Erschienen: 2012-04-25 00:00:00
ISSN
1438-9029
DOI
10.1055/s-0032-1311119

Zusammenfassung

Ziele: The role of additional radiotherapy after chemotherapy for advanced-stage Hodgkin lymphoma (HL) is unclear. The German Hodgkin Study Group (GHSG) thus performed the HD15 trial in which advanced-stage HL patients having residual disease after 6–8 cycles of BEACOPP were evaluated by 18F-FDG-PET following chemotherapy. Methode: Entry criteria for the PET question in HD15 were partial remission after the end of chemotherapy with at least one involved nodal site measuring more than 2.5cm in diameter by CT. A total of 2182 patients with de novo HL were included in HD15 of whom 740 wee qualified for the PET ques…

Schlagworte

After Tumor RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Ver…